Brentuximab vedotin for Hodgkin lymphoma in children and young adults
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 2 to under 35 years old
- You must have been diagnosed with classical Hodgkin lymphoma by at least two hospitals
- Your organs must be working well enough for treatment
- You or your guardian must agree to join the study
- You cannot have nodular lymphocyte-predominant Hodgkin lymphoma
- You cannot be pregnant, breastfeeding, or have an immune problem like HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted antibody-drug (brentuximab vedotin) plus standard chemotherapy (R-CHP) for people with a specific type of aggressive lymphoma that has a virus (EBV) in the tumor cells. The goal is to see if this combination works better than standard treatment.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This trial tests a drug called brentuximab vedotin (BV) in people whose Hodgkin lymphoma has come back or not responded to treatment. It aims to see if BV can help shrink or control the cancer.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.